Objective: Serum uric acid (UA), which is the final product of purine metabolism, is a predictor of left-sided heart failure (HF), as well as being a marker of outcomes and survival in patients with heart failure with reduced ejection fraction (HFrEF). Right-sided HF may or may not accompany HFrEF, but is associated with worse prognosis and increased morbidity and mortality when present. All available data for the association between RHF and UA are derived from patients with pulmonary arterial hypertension, and virtually no data is available for patients with HFrEF. Our aim was to understand the relationships between UA, echocardiographic markers of right ventricular systolic function and RHF in patients with HFrEF. Material and Methods: A total of 45 patients with an ejection fraction <40% and signs of HF were included. Patients were divided into tertiles according to serum UA concentration. RHF was defined according to the modified Interagency Registry for Mechanically Assisted Circulatory Support criteria. Results: Compared to patients within the lowest UA tertile, patients within the 3rd tertile had a significantly higher incidence of RHF (50.0% vs. 0.0%, Bonferroni-corrected p=0.009) and a significantly lower tricuspid annular plane systolic excursion (20.5±4.4 vs. 16.1±4.4, p=0.02). After adjusting for relevant clinical, demographic, laboratory and echocardiographic variables, serum UA remained a significant predictor of RHF [odds ratio: 2.89, 95% confidence interval (CI): 1.21-6.91, p=0.017]. For serum UA, the c-statistic for determination of RHF was 0.83 (95% CI: 0.71-0.96). Conclusion: Serum UA is associated with the occurrence of RHF in patients with HFrEF.
Keywords: Heart failure with reduced ejection fraction; right heart failure; echocardiography; uric acid
Amaç: Pürin metabolizmasının nihai ürünü olan ürik asit (ÜA), sol taraflı kalp yetersizliğinin bir prediktörü ve düşük ejeksiyon fraksiyonlu kalp yetersizliğinde (DEFKY) sonlanım ve sağkalımın bir göstergesidir. Sağ taraflı kalp yetersizliği (SğKY) sol kalp yetersizliği ile beraber görülebilir veya görülmeyebilir, ancak görüldüğü taktirde kötü prognoz ve artmış morbidite ve mortalite ile ilişkilidir. SğKY ve ÜA arasındaki ilişkiyi araştıran çalışmaların tamamı pulmoner hipertansiyonlu hastalar üzerinde yapılmıştır ve DEFKY'li hasta grubunda olası bir ilişkiyi gösteren veri yoktur. Bu çalışmada amacımız, DEF-KY'li hastalarda serum ÜA, sağ ventrikül fonksiyonunun ekokardiyografik göstergeleri ve SğKY arasındaki ilişki araştırılmaktır. Gereç ve Yöntemler: Ejeksiyon fraksiyonunun 40%'ın altında olduğu ve kalp yetersizliği bulguları olan 45 DEFKY hastası çalışmaya dahil edilmiştir. Hastalar serum ÜA seviyelerine göre üç eşit gruba ayrılmışlardır. SğKY''nin tanımlanması için, modifiye edilmiş ''Interagency Registry for Mechanically Assisted Circulatory Support'' kriterleri kullanılmıştır. Bulgular: En düşük ÜA grubu ile karşılaştırıldığında, 3. gruptaki hastalarsa SğKY sıklığı anlamlı olarak daha fazla bulunmuştur (50.0% - 0.0%, Bonferroni-düzeltilmiş p=0.009) ve aynı grupta triküspit düzlem sistolik hareketi anlamlı olarak azdır (20.5 ± 4.4 - 16.1 ± 4.4, p=0.02). Klinik, demografik, laboratuvar ve ekokardiyografik değişkenler istatistiksel olarak düzeltildikten sonra dahi, serum ÜA düzeyi SğKY için istatistiksel olarak anlamlı bir öngördürücü olmuştur (OO:2.89, 95%GA:1.21 -6.91, p=0.017). SğKY''nin belirlenmesi için serum ÜA''nın c-istatistiği 0.83'tür (95%GA: 0.71 - 0.96). Sonuç: Serum ÜA, DEFKY hastalarında SğKY ile ilişkili bulunmuştur.
Anahtar Kelimeler: Düşük ejeksiyon fraksiyonlu kalp yetersizliği; sağ kalp yetersizliği; ekokardiyografi; ürik asit
- Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J. 2008;275(13):3278-89. [Crossref] [PubMed]
- Battelli MG, Polito L, Bortolotti M, Bolognesi A. Xanthine oxidoreductase-derived reactive species: physiological and pathological effects. Oxid Med Cell Longev. 2016;2016:3527579. [Crossref] [PubMed] [PMC]
- Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995;141(7):637-44. [Crossref] [PubMed]
- Kuo CF, See LC, Yu KH, Chou IJ, Chiou MJ, Luo SF. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford). 2013;52(1):127-34. [Crossref] [PubMed]
- Ekundayo OJ, Dell'Italia LJ, Sanders PW, Arnett D, Aban I, Love TE, et al. Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol. 2010;142(3):279-87. [Crossref] [PubMed] [PMC]
- Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107(15):1991-7. [Crossref] [PubMed]
- Tamariz L, Harzand A, Palacio A, Verma S, Jones J, Hare J. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011;17(1):25-30. [Crossref] [PubMed]
- Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric acid and cardiovascular disease: an update. Eur Cardiol. 2016;11(1):54-9. [Crossref] [PubMed] [PMC]
- Yu W, Cheng JD. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol. 2020;11:582680. [Crossref] [PubMed] [PMC]
- Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2018;137(20):e578-e622. [Crossref] [PubMed]
- Naser A, Güvenç TS, Isgandarov K, Ekmekçi A, Gündüz S, Çetin Güvenç R, et al. Lack of right ventricular hypertrophy is associated with right heart failure in patients with left ventricular failure. Heart Vessels. 2022;37(10):1728-39. [Crossref] [PubMed]
- Accessed 15 Oct 2023. [Link]
- Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16(1):15-24. [Crossref] [PubMed]
- Fujihashi T, Sakata Y, Nochioka K, Miura M, Abe R, Kasahara S, et al; CHART-2 Investigators. Prognostic impacts of serum uric acid levels in patients with chronic heart failure: insights from the CHART-2 study. ESC Heart Fail. 2021;8(2):1027-38. [Crossref] [PubMed] [PMC]
- Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, et al; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301-9. [Crossref] [PubMed]
- Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, et al; NHLBI heart failure clinical research network. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase ınhibition for hyperuricemic heart failure patients (EXACT-HF) Study. Circulation. 2015;131(20):1763-71. [Crossref] [PubMed] [PMC]
- White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200-10. [Crossref] [PubMed]
- Cantu-Medellin N, Kelley EE. Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation. Redox Biol. 2013;1(1):353-8. [Crossref] [PubMed] [PMC]
- Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010;333(1-2):191-201. [Crossref] [PubMed]
- Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942-54. [Crossref] [PubMed] [PMC]
- Mehra MR, Park MH, Landzberg MJ, Lala A, Waxman AB; International Right Heart Failure Foundation Scientific Working Group. Right heart failure: toward a common language. J Heart Lung Transplant. 2014;33(2):123-6. [Crossref] [PubMed]
- Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis. 2006;65(8):981-2. [Crossref] [PubMed] [PMC]
- Felker GM, O'Connor CM, Braunwald E; Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2(1):56-62. [Crossref] [PubMed] [PMC]
.: Process List